Picture of DNA strand

Pioneering chemical biology & medicinal chemistry through Open Access research...

Strathprints makes available scholarly Open Access content by researchers in the Department of Pure & Applied Chemistry, based within the Faculty of Science.

Research here spans a wide range of topics from analytical chemistry to materials science, and from biological chemistry to theoretical chemistry. The specific work in chemical biology and medicinal chemistry, as an example, encompasses pioneering techniques in synthesis, bioinformatics, nucleic acid chemistry, amino acid chemistry, heterocyclic chemistry, biophysical chemistry and NMR spectroscopy.

Explore the Open Access research of the Department of Pure & Applied Chemistry. Or explore all of Strathclyde's Open Access research...

Children's brain tumour drug delivery consortium

Rahman, Ruman and Grundy, Richard and Campbell, Emma and Brem, Henry and Pearl, Monica and Green, Jordan and Janoski, Miroslav and Cohen, Kenneth and Walczak, Piotr and Warren, Katherine and Lowis, Stephen and Mullen, Alexander and Boyd, Marie and Veal, Gareth and Hargrave, Darren and van Vuurden, Dannis and Powell, Stephen and Walker, David (2017) Children's brain tumour drug delivery consortium. Neuro-Oncology, 19 (suppl). iv52. ISSN 1522-8517

[img] Text (Rahman-etal-NO-2017-Childrens-brain-tumour-drug-delivery)
Rahman_etal_NO_2017_Childrens_brain_tumour_drug_delivery.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 1 June 2019.

Download (293kB) | Request a copy from the Strathclyde author

    Abstract

    INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non toxic concentrations for sufficient duration to achieve the biological effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they account for over 20% of childhood cancer and differ significantly in their biological characteristics from their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were encouraged to develop a proposal, to establish an international research consortium to raise awareness and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an international, multi-disciplinary network of clinicians and researchers within pharma and academia as well as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by working closely with the international children’s brain tumour community. CONCLUSION: We present this abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators to promote this research priority for children across the world and to consider joining the consortium, which will be presented at the conference.